Literature DB >> 20717915

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

Donald R VanDevanter1, Jeffrey S Wagener, David J Pasta, Eric Elkin, Joan R Jacobs, Wayne J Morgan, Michael W Konstan.   

Abstract

RATIONALE: Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management.
OBJECTIVES: To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP(2-5)) and lung function change over a 4-year period in patients aged 6-17 years (POP(6-17)).
METHODS: Analyses were conducted using patients from the Epidemiologic Study of CF (ESCF). To be included in any analysis, patients had to have 1 year of clinical history recorded in ESCF prior to a clinically stable routine Index Clinic Visit (ICV). In addition to this criterion, for the POP(2-5) tool patients had to be between 2 and 5 years old at ICV and have a second clinically stable visit with spirometric measures at age 6. For the POP(6-17) tool, patients had to be between the ages of 6 and 17 years old at an ICV that included spirometric measures and had to have a second clinically stable visit with spirometric measures from 3 to 5 years after ICV. All patients enrolled in ESCF who met these inclusion criteria were studied. POP(2-5) and POP(6-17) populations were further divided into development groups (with ICV before January 1, 1998) and validation groups (with ICV after that date). Development groups were used to model forced expiratory volume in 1 sec (FEV(1)) percent predicted at age 6 years (for POP(2-5)) and annualized FEV(1) % predicted change from ICV to the second visit (for POP(6-17)) by multivariable linear regression using age, sex, weight-for-age percentile, cough, sputum production, clubbing, crackles, wheeze, sinusitis, number of exacerbations requiring intravenous antibiotics in the past year, elevated liver enzymes, pancreatic enzyme use, and respiratory tract culture status, plus height-for-age percentile (POP(2-5)) and index FEV(1) (POP(6-17)). Integer-based POP(2-5) and POP(6-17) tools created from selected variables were evaluated by Pearson correlation and then prospectively validated with separate data collected later from ESCF patients with ICV after January 1, 1998. MAIN
RESULTS: POP(2-5) and POP(6-17) development groups included 2,709 and 6,113 patients and validation groups included 3,458 and 7,086 patients, respectively. Variables retained were weight-for-age percentile, clubbing, crackles, wheeze, number of exacerbations, and Pseudomonas aeruginosa culture status (both tools), daily cough (POP(2-5)), and age, sex, and index FEV(1) % predicted (POP(6-17)). Correlation coefficients for POP(2-5) and POP(6-17) tools prospectively applied to validation groups were +0.32 and +0.37, respectively.
CONCLUSIONS: These simple integer-based POP algorithms employ variables available at clinic visits and can be used to predict the probability of different future pulmonary outcomes for individual patients and patient populations.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20717915      PMCID: PMC4112577          DOI: 10.1002/ppul.21311

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  37 in total

Review 1.  An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.

Authors:  Nicole Beydon; Stephanie D Davis; Enrico Lombardi; Julian L Allen; Hubertus G M Arets; Paul Aurora; Hans Bisgaard; G Michael Davis; Francine M Ducharme; Howard Eigen; Monika Gappa; Claude Gaultier; Per M Gustafsson; Graham L Hall; Zoltán Hantos; Michael J R Healy; Marcus H Jones; Bent Klug; Karin C Lødrup Carlsen; Sheila A McKenzie; Francçois Marchal; Oscar H Mayer; Peter J F M Merkus; Mohy G Morris; Ellie Oostveen; J Jane Pillow; Paul C Seddon; Michael Silverman; Peter D Sly; Janet Stocks; Robert S Tepper; Daphna Vilozni; Nicola M Wilson
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

2.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

3.  Reference ranges for spirometry across all ages: a new approach.

Authors:  Sanja Stanojevic; Angie Wade; Janet Stocks; John Hankinson; Allan L Coates; Huiqi Pan; Mark Rosenthal; Mary Corey; Patrick Lebecque; Tim J Cole
Journal:  Am J Respir Crit Care Med       Date:  2007-11-15       Impact factor: 21.405

4.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

5.  Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

Authors:  Michael W Konstan; Mark D Schluchter; Wei Xue; Pamela B Davis
Journal:  Am J Respir Crit Care Med       Date:  2007-09-13       Impact factor: 21.405

6.  Endometriosis fertility index: the new, validated endometriosis staging system.

Authors:  G David Adamson; David J Pasta
Journal:  Fertil Steril       Date:  2010-10       Impact factor: 7.329

7.  Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.

Authors:  Clement L Ren; David J Pasta; Lawrence Rasouliyan; Jeffrey S Wagener; Michael W Konstan; Wayne J Morgan
Journal:  J Pediatr       Date:  2008-08-30       Impact factor: 4.406

8.  Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005.

Authors:  Donald R VanDevanter; Lawrence Rasouliyan; Thomas M Murphy; Wayne J Morgan; Clement L Ren; Michael W Konstan; Jeffrey S Wagener
Journal:  Pediatr Pulmonol       Date:  2008-08

Review 9.  Endpoints for clinical trials in young children with cystic fibrosis.

Authors:  Stephanie D Davis; Alan S Brody; Mary J Emond; Lyndia C Brumback; Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

10.  Characterizing aggressiveness and predicting future progression of CF lung disease.

Authors:  Michael W Konstan; Jeffrey S Wagener; Donald R VanDevanter
Journal:  J Cyst Fibros       Date:  2009-06       Impact factor: 5.482

View more
  19 in total

1.  Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Alan S Brody; Philip M Farrell
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

2.  Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.

Authors:  Thida Ong; Michael Schechter; Jing Yang; Limin Peng; Julia Emerson; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatrics       Date:  2017-01-16       Impact factor: 7.124

3.  Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

Review 4.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

5.  New severity assessment in cystic fibrosis: signal intensity and lung volume compared to LCI and FEV1: preliminary results.

Authors:  Sabrina Fleischer; Mareen Sarah Kraus; Sergios Gatidis; Winfried Baden; Andreas Hector; Dominik Hartl; Ilias Tsiflikas; Juergen Frank Schaefer
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

6.  Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Authors:  Don B Sanders; George M Solomon; Valeria V Beckett; Natalie E West; Cori L Daines; Sonya L Heltshe; Donald R VanDevanter; Jonathan E Spahr; Ronald L Gibson; Jerry A Nick; Bruce C Marshall; Patrick A Flume; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2017-04-29       Impact factor: 5.482

7.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08

8.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

10.  Effects of Autogenic Drainage on Sputum Recovery and Pulmonary Function in People with Cystic Fibrosis: A Systematic Review.

Authors:  Kimbly Morgan; Kristin Osterling; Robert Gilbert; Gail Dechman
Journal:  Physiother Can       Date:  2015       Impact factor: 1.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.